Tag Archives: subcutaneous formulation of RoACTEMRA

Roche subcutaneous formulation of RoACTEMRA received European Commission approval for moderate to severe rheumatoid arthritis treatment

First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy Basel, 29-4-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the subcutaneous formulation of RoACTEMRA (tocilizumab) has received approval from … Read the full press release